The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

Overview

Journal Front Pharmacol

Date 2021 Apr 12

PMID 33841154

Citations 4

Authors

Hongmei Cui

Qinghui Wang

Duane D Miller

Wei Li

Affiliations

Soon will be listed here.

Abstract

Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15-20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma. However, most patients develop acquired resistance to Vem within 6-9 months. Therefore, developing a new treatment strategy to overcome Vem-resistance is highly significant. Our previous study reported that the combination of a tubulin inhibitor ABI-274 with Vem showed a significant synergistic effect to sensitize Vem-resistant melanoma both and . In the present study, we unveiled that VERU-111, an orally bioavailable inhibitor of α and β tubulin that is under clinical development, is highly potent against Vem-resistant melanoma cells. The combination of Vem and VERU-111 resulted in a dramatically enhanced inhibitory effect on cancer cells and Vem-resistant melanoma tumor growth compared with single-agent treatment. Further molecular signaling analyses demonstrated that in addition to ERK/AKT pathway, Skp2 E3 ligase also plays a critical role in Vem-resistant mechanisms. Knockout of Skp2 diminished oncogene AKT expression and contributed to the synergistic inhibitory effect of Vem and VERU-111. Our results indicate a treatment combination of VERU-111 and Vem holds a great promise to overcome Vem-resistance for melanoma patients harboring BRAF (V600E) mutation.

Citing Articles

Complex Inhibitory Activity of Pentacyclic Triterpenoids against Cutaneous Melanoma In Vitro and In Vivo: A Literature Review and Reconstruction of Their Melanoma-Related Protein Interactome.

Moralev A, Zenkova M, Markov A ACS Pharmacol Transl Sci. 2024; 7(11):3358-3384.

PMID: 39539268 PMC: 11555519. DOI: 10.1021/acsptsci.4c00422.

Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review.

Jing J, Rui L, Junyuan S, Jinfeng Y, Zhihao H, Weiguo L Front Pharmacol. 2023; 14:1122008.

PMID: 37089937 PMC: 10113621. DOI: 10.3389/fphar.2023.1122008.

Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer.

Niu X, Wu T, Yin Q, Gu X, Li G, Zhou C Cells. 2022; 11(19).

PMID: 36231056 PMC: 9563422. DOI: 10.3390/cells11193094.

Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.

Wu T, Li C, Zhou C, Niu X, Li G, Zhou Y Cell Biol Toxicol. 2022; 39(5):2381-2399.

PMID: 35648318 DOI: 10.1007/s10565-022-09729-x.

References

Trojaniello C, Festino L, Vanella V, Ascierto P . Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Expert Rev Clin Pharmacol. 2019; 12(3):259-266. DOI: 10.1080/17512433.2019.1570847. View

Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X . Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer. 2014; 110(8):1958-67. PMC: 3992499. DOI: 10.1038/bjc.2014.136. View

Byun W, Jin M, Yu J, Kim W, Song J, Chung H . A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer. Biochem Pharmacol. 2018; 158:84-94. DOI: 10.1016/j.bcp.2018.10.002. View

Yang Y, Lu Y, Wang L, Mizokami A, Keller E, Zhang J . Skp2 is associated with paclitaxel resistance in prostate cancer cells. Oncol Rep. 2016; 36(1):559-66. DOI: 10.3892/or.2016.4809. View

Chen J, Wang Z, Li C, Lu Y, Vaddady P, Meibohm B . Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J Med Chem. 2010; 53(20):7414-27. PMC: 2964152. DOI: 10.1021/jm100884b. View

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

Johnson G, Stuhlmiller T, Angus S, Zawistowski J, Graves L . Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Clin Cancer Res. 2014; 20(10):2516-22. PMC: 4024346. DOI: 10.1158/1078-0432.CCR-13-1081. View

Krishnegowda G, Gowda A, Tagaram H, Carroll K, Irby R, Sharma A . Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway. Bioorg Med Chem. 2011; 19(20):6006-14. PMC: 3235409. DOI: 10.1016/j.bmc.2011.08.044. View

Kashyap V, Wang Q, Setua S, Nagesh P, Chauhan N, Kumari S . Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Cancer Res. 2019; 38(1):29. PMC: 6343279. DOI: 10.1186/s13046-018-1009-7. View

10.

Cui H, Arnst K, Miller D, Li W . Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance. Curr Med Chem. 2020; 27(39):6573-6595. DOI: 10.2174/0929867326666191016113631. View

11.

Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S . Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel). 2020; 12(2). PMC: 7072236. DOI: 10.3390/cancers12020482. View

12.

Wu J, Huang Y, Zhou X, Zhang W, Lian Y, Lv X . Skp2 is required for Aurora B activation in cell mitosis and spindle checkpoint. Cell Cycle. 2015; 14(24):3877-84. PMC: 4825700. DOI: 10.1080/15384101.2015.1120916. View

13.

Chen H, Deng S, Wang Y, Albadari N, Kumar G, Ma D . Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties. J Med Chem. 2019; 63(2):827-846. DOI: 10.1021/acs.jmedchem.9b01815. View

14.

Simeone E, Grimaldi A, Festino L, Vanella V, Palla M, Ascierto P . Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. BioDrugs. 2017; 31(1):51-61. DOI: 10.1007/s40259-016-0208-z. View

15.

Bhalla K . Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003; 22(56):9075-86. DOI: 10.1038/sj.onc.1207233. View

16.

Kawaguchi K, Igarashi K, Murakami T, Kiyuna T, Lwin T, Hwang H . MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Oncotarget. 2017; 8(29):47490-47496. PMC: 5564580. DOI: 10.18632/oncotarget.17667. View

17.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G . eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature. 2014; 513(7516):105-9. DOI: 10.1038/nature13572. View

18.

Faghfuri E, Nikfar S, Niaz K, Faramarzi M, Abdollahi M . Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors. Expert Opin Drug Metab Toxicol. 2018; 14(3):317-330. DOI: 10.1080/17425255.2018.1432593. View

19.

Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sales F . p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98-110. DOI: 10.1016/j.ejca.2015.12.002. View

20.

Thang N, Van Minh N, Huong P . Translocation of BBAP from the cytoplasm to the nucleus reduces the metastatic ability of vemurafenib-resistant SKMEL28 cells. Mol Med Rep. 2016; 15(1):317-322. DOI: 10.3892/mmr.2016.5976. View